There's no current licensed vaccine to stop the Ebola virus, according to WHO. But there are some experimental treatments.
The two U.S. aid workers now being treated at Emory have been given Zmapp. The treatment is a mixture of three antibodies against the Ebola virus, produced in bioengineered tobacco plants.
Another experimental drug, developed by the Canadian firm Tekmira Pharmaceuticals has been tested on monkeys and on some non-Ebola infected humans.
The drug is designed to target the strands of genetic material of the virus (RNA). An early safety trial has been put on hold because the Food and Drug Administration has requested more data.
And the American based pharmaceutical company Sarepta Therapeutics is working on a similar treatment. It has been tested in healthy human volunteers, but not on an Ebola patient.
Read MoreSpanish Ebola patient stable in Madrid hospital
But for now, treatment is usually strict isolation of patients, while giving them intravenous fluids to stop dehydration along with antibiotics to fight infections.
Most experts say the U.S. is immune from a deadly outbreak of Ebola, similar to what's happening in West Africa.
That's because the U.S. has a more highly refined and sophisticated medical system that would catch the disease before it could spread, the experts say.
But that sentiment comes with a warning.
"Americans should still be on the alert," said Cecilia Rokusek, assistant dean for education, planning and research at Nova Southeastern University in Florida.
"We can no longer become complacent to any public health danger anywhere," she said.
—By CNBC's Mark Koba